Geron Corporation (NasdaqGS: GERN)
Health Care · Biotechnology · US
$1.52
-1.94% today · +4.1% 1Y
Geron Corporation (NasdaqGS: GERN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $976.56M and employs 258 people.
Over the last twelve months the share price has gained 4.1%, trading between 1.04 and 2.01.
Tweenvest scores Geron Corporation across four factors: quality 28/100, value 74/100, growth 100/100. Its strongest factor is growth.
GERN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $976.56M
- Revenue (TTM)
- $204.56M
- P/E
- —
- EPS
- -0.10
- Dividend yield
- —
- Beta (5Y)
- 0.59
- 52-week high
- $2.01
- 52-week low
- $1.04
- Avg volume (3M)
- —
- Shares outstanding
- 642.47M
- Employees
- 258
- Next earnings
- —
About Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
- ISIN
- US3741631036
- Founded
- 1990
- Listed since
- Jul 31, 1996
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.31 | +0.51% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.